Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 12/20 | 0.68 |
| ▸ | MKNK2 | Q9HBH9 | 10/20 | 0.68 |
| ▸ | KRAS | P01116 | 2/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21554504 | 0.90 | MKNK1 (0.66) | MKNK1MKNK2KRASRPS6KA5PDE10A | |
| SCHEMBL21554403 | 0.81 | MKNK1 (0.74) | MKNK1MKNK2 | |
| SCHEMBL22722391 | 0.81 | MKNK1 (1.00) | MKNK1MKNK2KRASALDH1A1TYK2 | |
| SCHEMBL21554502 | 0.79 | MKNK1 (0.88) | MKNK1MKNK2PDE10A | |
| SCHEMBL22722372 | 0.72 | MKNK1 (0.77) | MKNK1MKNK2 | |
| SCHEMBL21554500 | 0.71 | MKNK1 (0.68) | MKNK1MKNK2 | |
| SCHEMBL21554435 | 0.70 | MKNK1 (0.51) | MKNK1MKNK2PDE10AALDH1A1TYK2 | |
| SCHEMBL22722381 | 0.69 | MKNK1 (1.00) | MKNK1MKNK2 | |
| SCHEMBL22722377 | 0.68 | MKNK1 (0.72) | MKNK1MKNK2 | |
| SCHEMBL20479141 | 0.67 | MKNK1 (1.00) | MKNK1MKNK2RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851082-B2 | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) | NORTHWESTERN UNIVERSITY (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3564235-A1 | SUBSTITUTED AROMATIC N-HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE INTERACTING KINASE 1 (MNK1) AND 2 (MNK2) | Northwestern University (US) | 2019-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851082-B2 | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) | MAP4K2, MAP3K20, MKNK2 | MKNK1 5/4885MKNK2 3/4885KRAS 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.